# Jean Trédaniel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jean-tredaniel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,438 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 36 |
| i10-index | 74 |
| Last Known Institution | Hôpital Paris Saint-Joseph |
| OpenAlex ID | https://openalex.org/A5023080520 |
| ORCID iD | 0000-0003-1369-5668 |
| Works | 210 |

## Researcher papers

- [Tobacco smoke and involuntary smoking](https://scholariq.org/papers/tobacco-smoke-and-involuntary-smoking/)
- [Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial](https://scholariq.org/papers/carboplatin-and-weekly-paclitaxel-doublet-chemotherapy-compared-with-monotherapy/)
- [Serum p53 antibodies as early markers of lung cancer](https://scholariq.org/papers/serum-p53-antibodies-as-early-markers-of-lung-cancer/)
- [Tobacco smoking and gastric cancer: Review and meta-analysis](https://scholariq.org/papers/tobacco-smoking-and-gastric-cancer-review-and-meta-analysis/)
- [Multicenter Case-Control Study of Exposure to Environmental Tobacco Smoke and Lung Cancer in Europe](https://scholariq.org/papers/multicenter-case-control-study-of-exposure-to-environmental-tobacco-smoke-and/)
- [Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer](https://scholariq.org/papers/cisplatin-increases-pd-l1-expression-and-optimizes-immune-check-point-blockade/)
- [Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study](https://scholariq.org/papers/bevacizumab-in-patients-with-nonsquamous-non-small-cell-lung-cancer-and/)
- [Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002](https://scholariq.org/papers/noninvasive-diagnosis-of-actionable-mutations-by-deep-sequencing-of-circulating/)
- [Risk of childhood cancer and adult lung cancer after childhood exposure to passive smoke: A meta-analysis.](https://scholariq.org/papers/risk-of-childhood-cancer-and-adult-lung-cancer-after-childhood-exposure-to/)
- [Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations](https://scholariq.org/papers/vemurafenib-in-non-small-cell-lung-cancer-patients-with-brafv600-and-brafnonv600/)
- [Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study](https://scholariq.org/papers/histomolecular-resistance-mechanisms-to-first-line-osimertinib-in-egfr-mutated/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Smoking Behavior and Cessation](https://scholariq.org/topics/smoking-behavior-and-cessation/)

## Researcher university

- [Hôpital Paris Saint-Joseph](https://scholariq.org/institutions/hopital-paris-saint-joseph/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.